Programmatic Upstream Liquid Biopsy Molecular Testing in Lung Cancer
This document explores the critical role of molecular testing in lung cancer treatment, emphasizing the importance of next-generation sequencing (NGS) and liquid biopsy for accurate and timely decision-making. It examines advancements in molecular testing, identifies gaps in current practices that hinder optimal patient outcomes, and discusses the implications of tumor biology on treatment strategies. Additionally, the document highlights the necessity of integrating molecular insights into early-stage lung cancer care and underscores how tumor biology can be a stronger prognostic factor than anatomical staging.